A Phase 1/2 interventional study of Idelalisib in Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma and Small Lymphocytic Lymphoma, sponsored by Gilead Sciences. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by Gilead Sciences · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing idelalisib in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. idelalisib · Lymphoma, Follicular.
Among the 12 studies testing idelalisib in Lymphoma, Follicular, this one is the 6th largest by enrollment, is one of 2 that started in 2011, is the only one in phase 1/2, and was the 2nd registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →None of the 12 studies testing idelalisib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3
First in 2011; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 18 across the 12 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 6 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
17 studies in Lymphoma, Follicular by Gilead Sciences: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 9 (69%) have results posted.
Among the 17 studies in Lymphoma, Follicular by Gilead Sciences, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2011, is one of 3 in phase 1/2, and was the 6th registered.
Gilead Sciences’s Lymphoma, Follicular studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing idelalisib in Lymphoma, Follicular, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 17 in Lymphoma, Follicular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study is to evaluate the safety and efficacy of idelalisib (GS-1101, CAL-101) in participants with previously treated indolent non-Hodgkin lymphoma (iNHL).
Eligible patients will initiate oral therapy with idelalisib at a starting dose of 150 mg twice per day. Treatment with idelalisib can continue in compliant participants for up to twelve 28-day cycles of idelalisib. Participants who appear to be benefiting from treatment at the completion of 12 cycles of treatment with idelalisib may be eligible for participation in a long-term safety extension study of idelalisib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Idelalisib
Tablet(s) administered orally twice daily
Also known as: GS-1101, CAL-101, Zydelig®
Overall Safety of Idelalisib
The overall safety of idelalisib was assessed as the percentage of participants experiencing treatment-emergent adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib).
Time frame: 30 days post last study treatment (up to 12 months)
Clinical Response: Overall Response Rate
Participants were assessed for clinical response by appropriate imaging at the end of cycles 3, 6, 9, and 12. Overall response rate (ORR) was assessed based on standardized criteria (Cheson 2007), and was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) based on investigator assessment after the start of idelalisib treatment until progression or the end of study drug treatment. * CR was defined as the disappearance of all evidence of disease. * PR was defined the regression of measurable disease and no new sites.
Time frame: Up to twelve 28-day cycles (maximum of 12 months)
Flow Cytometric Measurement of Constitutive or Inducible Phosphorylation of Akt (at S473) and S6 Within Tumor B Cells
Time frame: Up to twelve 28-day cycles (maximum of 12 months)
Flow Cytometric Measurement of Tumoral and Peripheral Blood T and NK Cells
Time frame: Up to twelve 28-day cycles (maximum of 12 months)
Changes in Concentration of Peripheral Blood Chemokines and Cytokines
Time frame: Up to twelve 28-day cycles (maximum of 12 months)
Changes in Liver Imaging as Assessed by Magnetic Resonance Imaging (MRI) and Gadoxetic Acid (GD-EOB-DTPA) Contrast
Time frame: Up to twelve 28-day cycles (maximum of 12 months)
Participants were enrolled at 2 study sites in the United States. The first participant was screened on 22 February 2011. The last study visit occurred on 24 August 2015.
| Milestone | Idelalisib |
|---|---|
| Started | 18 |
| Completed | 5 |
| Not completed | 13 |
| Withdrew: Adverse event | 5 |
| Withdrew: Disease progression | 7 |
| Withdrew: Other: change in eligibility status | 1 |
The overall safety of idelalisib was assessed as the percentage of participants experiencing treatment-emergent adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib).
| percentage of participants | Idelalisib |
|---|---|
| Any AE | 88.9 |
| Serious AE | 27.8 |
| Grade ≥ 3 AE | 55.6 |
| AE related to idelalisib | 83.3 |
| AE leading to permanent drug discontinuation | 27.8 |
Participants were assessed for clinical response by appropriate imaging at the end of cycles 3, 6, 9, and 12. Overall response rate (ORR) was assessed based on standardized criteria (Cheson 2007), and was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) based on investigator assessment after the start of idelalisib treatment until progression or the end of study drug treatment. * CR was defined as the disappearance of all evidence of disease. * PR was defined the regression of measurable disease and no new sites.
| percentage of participants | Idelalisib |
|---|---|
| Clinical Response: Overall Response Rate | 44.4 (21.5 to 69.2) |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over 30 days post last study treatment (up to 12 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib | — | 5/18 (27.8%) | 15/18 (83.3%) |
| Event | Idelalisib |
|---|---|
| Tumour lysis syndromeMetabolism and nutrition disorders | 2/18 |
| Renal failureRenal and urinary disorders | 2/18 |
| Atrial fibrillationCardiac disorders | 1/18 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/18 |
| CellulitisInfections and infestations | 1/18 |
| SepsisInfections and infestations | 1/18 |
| Alanine aminotransferase increasedInvestigations | 1/18 |
| Aspartate aminotransferase increasedInvestigations | 1/18 |
| Transaminases increasedInvestigations | 1/18 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/18 |
| Event | Idelalisib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 8/18 |
| FatigueGeneral disorders | 8/18 |
| Alanine aminotransferase increasedInvestigations | 8/18 |
| Aspartate aminotransferase increasedInvestigations | 8/18 |
| NauseaGastrointestinal disorders | 7/18 |
| VomitingGastrointestinal disorders | 5/18 |
| PyrexiaGeneral disorders | 5/18 |
| InsomniaPsychiatric disorders | 5/18 |
| RashSkin and subcutaneous tissue disorders | 5/18 |
| Upper respiratory tract infectionInfections and infestations | 4/18 |
Intent-to-treat (ITT) Analysis Set: all enrolled participants who received at least 1 dose of idelalisib.
| Age, Continuous(years) | Idelalisib |
|---|---|
| Mean | 58 ± 12.6 |
| Sex: Female, Male(Participants) | Idelalisib |
|---|---|
| Female | 8 |
| Male | 10 |
| Diagnosis(participants) | Idelalisib |
|---|---|
| Follicular lymphoma | 10 |
| Marginal zone lymphoma | 3 |
| Small lymphocytic lymphoma | 4 |
| Missing | 1 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
No publications or documents are linked to this record.
The record gives a start of Feb 2011, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib